Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis.
Fujita K, Imajo K, Shinohara Y, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Abe Y, Inamori M, Shimamura T, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A. Fujita K, et al. Among authors: inamori m. J Pharmacol Sci. 2011;115(3):270-3. doi: 10.1254/jphs.10r14fm. Epub 2011 Feb 22. J Pharmacol Sci. 2011. PMID: 21350309 Free article. Review.
Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H. Inamori M, et al. J Gastroenterol Hepatol. 2003 Sep;18(9):1034-8. doi: 10.1046/j.1440-1746.2003.03126.x. J Gastroenterol Hepatol. 2003. PMID: 12911659 Clinical Trial.
Evaluation of the effects of anti-secretory drugs on intragastric acidity: is combined therapy with a proton pump inhibitor and an H2 receptor antagonist effective as initial treatment?
Inamori M, Togawa J, Chiguchi G, Abe Y, Kikuchi T, Muramatsu K, Kawamura H, Kobayashi N, Kirikoshi H, Shimamura T, Sakaguchi T, Takamura T, Ueno N, Nakajima A. Inamori M, et al. J Gastroenterol. 2005 Feb;40(2):213-4. doi: 10.1007/s00535-004-1521-8. J Gastroenterol. 2005. PMID: 15770408 No abstract available.
Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy.
Togawa J, Inamori M, Fujisawa N, Takahashi H, Yoneda M, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H. Togawa J, et al. Among authors: inamori m. Hepatogastroenterology. 2005 Mar-Apr;52(62):645-8. Hepatogastroenterology. 2005. PMID: 15816496 Clinical Trial.
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
Inamori M, Togawa J, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Shimamura T, Kubota K, Sakaguchi T, Saito S, Ueno N, Nakajima A. Inamori M, et al. J Gastroenterol. 2005 May;40(5):453-8. doi: 10.1007/s00535-005-1569-0. J Gastroenterol. 2005. PMID: 15942709 Clinical Trial.
321 results